Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific propri… Read more
Acrivon Therapeutics, Inc. Common Stock (ACRV) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.096x
Based on the latest financial reports, Acrivon Therapeutics, Inc. Common Stock (ACRV) has a cash flow conversion efficiency ratio of -0.096x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.28 Million) by net assets ($128.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Acrivon Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Acrivon Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Acrivon Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Acrivon Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Reliance Communications Limited
NSE:RCOM
|
0.000x |
|
Signetics Corporation
KQ:033170
|
-0.033x |
|
Affluent Partners Holdings Limited
OTCGREY:MNNGF
|
-0.047x |
|
BALSU GIDA
IS:BALSU
|
N/A |
|
Igarashi Motors India Limited
NSE:IGARASHI
|
0.099x |
|
MAISON POMMERY & ASSOCIES
PA:POMRY
|
-0.070x |
|
Sinsin Pharmaceutical Co. Ltd
KQ:002800
|
0.066x |
|
Woodlands Financial Services Co
PINK:WDFN
|
N/A |
Annual Cash Flow Conversion Efficiency for Acrivon Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual cash flow conversion efficiency of Acrivon Therapeutics, Inc. Common Stock from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $176.79 Million | $-65.67 Million | -0.371x | -5.58% |
| 2023-12-31 | $121.19 Million | $-42.64 Million | -0.352x | -99.16% |
| 2022-12-31 | $170.47 Million | $-30.12 Million | -0.177x | -130.08% |
| 2021-12-31 | $-23.81 Million | $-13.98 Million | 0.587x | +76.26% |
| 2020-12-31 | $-8.41 Million | $-2.80 Million | 0.333x | -- |